Navigation Links
Adamas Pharmaceuticals to Present Data on Triple Combination Antiviral Drug Therapy for Drug-Resistant Influenza at 2009 ICAAC Annual Meeting
Date:9/3/2009

EMERYVILLE, Calif., Sept. 3 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today that new research data will be delivered as an oral presentation during the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, CA on September 13, 2009. The presentation will describe results from a multi-institutional collaborative in vitro study of Adamas' triple combination antiviral drug (TCAD) therapy.

    Presentation details:

    Title:            Triple Combination of Amantadine, Ribavirin and
                      Oseltamivir Restores In Vitro Activity of Antiviral
                      Drugs against Resistant Influenza Viruses

    Date/Time:        Sunday, Sep 13, 2009, 10:45 AM -11:00 AM

    Session:          064-Respiratory Viruses and Influenza
                      Sunday, Sep 13, 2009, 8:30 AM -11:00 AM

    Abstract Number:  V-537b

    Location:         Marriott Salon 9

    Authors:          J. T. NGUYEN (1), J. HOOPES (2), D. SMEE (2),
                      M. LE (1), A. PATICK (1), M. DE JONG (3),
                      G. WENT (1), D. FAIX (4), P. BLAIR (4),
                      M. PRICHARD (5);
                      (1) Adamas Pharmaceuticals, Emeryville, CA,
                      (2) Utah State Univ., Logan, UT,
                      (3) Amsterdam Med. Ctr., Amsterdam, Netherlands,
                      (4) Naval Health Research Center, San Diego, CA,
                      (5) Univ. of Alabama, Birmingham, AL.

About TCAD

Adamas is pioneering triple-combination antiviral drug (TCAD) therapy for influenza, which is designed to inhibit viral replication at multiple points during the virus life cycle. TCAD therapy includes Adamas' investigational proprietary fixed-dose combination of amantadine and ribavirin, to be administered adjunctively with a neuraminidase inhibitor such as Tamiflu (oseltamivir phosphate, Roche). Preclinical data indicate that the in vitro combination of these drugs, each with their own mechanism of action, acts synergistically to provide a much higher level of antiviral activity than single or double drug combinations. In in vitro studies to date, TCAD therapy also has been found to provide greater antiviral activity across multiple strains of influenza, even those resistant to single pharmaceutical agents. Adamas is accelerating development of its TCAD therapy for influenza A by conducting a Phase 2 clinical trial in the Southern Hemisphere where the novel influenza A/H1N1 pandemic is active, and is preparing to initiate a clinical study of TCAD therapy for influenza A in North America during this upcoming flu season.

About Adamas

Adamas is an emerging pharmaceutical company focused on developing small molecule, Advantaged Therapeutics(TM) to treat neurological and infectious diseases, including influenza A, the cause of the current flu pandemic. Adamas' approach to pharmaceutical development is to identify synergistic drug mechanisms that can be developed as optimized combination drug therapies to increase safety, efficacy and compliance, thus improving upon the standard of care. Adamas is headquartered in Emeryville, California, with operations in Bangalore, India. For more information about Adamas, please visit www.adamaspharma.com.


'/>"/>
SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... ... ... NetDimensions appoints Bill Mastin, a learning technology veteran, as its new Senior Vice ... technologies industry, Mastin joins NetDimensions from the New York office of learning and engagement ... served as SVP of the North America offices and prior to that, he held ...
(Date:4/20/2017)... ... ... Parallel6™ , the leader in mClinical™ technologies for improving patient enrollment, ... of the 2017 Top 10 eClinical Trial Management Solution Providers by Pharma Tech ... take pride in honoring Parallel6 as one of the top 10 companies that are ...
(Date:4/20/2017)... Israel , April 20, 2017  BrainStorm ... stem cell technologies for neurodegenerative diseases, announced today that ... Alliance for Regenerative Medicine,s (ARM) 5 th Annual Cell ... at 09:40 EDT in Boston . ... Chief Medical Officer & Chief Operating Officer, will participate in ...
(Date:4/19/2017)... ... 2017 , ... A number of new instruments have recently emerged to accommodate ... Protein and Cell Analysis Education Webinar Series , will focus on advances in ... and future applications. , Many flow cytometers have unique capabilities and the Attune ...
Breaking Biology Technology:
(Date:3/9/2017)... Australia , March 9, 2017 ... the prestigious World Lung Imaging Workshop at the University ... , was invited to deliver the latest data to ... globally recognised event brings together leaders at the forefront ... developments in lung imaging. "The quality ...
(Date:3/7/2017)... 2017 Brandwatch , the leading social intelligence company, ... Trust to uncover insights to support its reporting, help direct ... The UK,s leading youth charity will be using Brandwatch Analytics social ... a better understanding of the topics and issues that are a ... ...
(Date:3/6/2017)... , March 6, 2017 Mintigo ... technology, today announced Predictive Sales Coach TM , ... actionable sales intelligence into Salesforce. This unique AI ... their sales organizations with deep knowledge of their ... for intelligent engagement. Predictive Sales Coach extends Mintigo,s ...
Breaking Biology News(10 mins):